Contents
Contents
Physician drug billing fraud involves knowingly billing government health programs for medication or administration that differs from what the practice supplied, or for drugs that were ineligible for reimbursement. The discrepancy may start with a free shipment, a shared vial, a smaller dose or a treatment that never happened. If you work in purchasing, nursing or billing, you may know where the drug’s story changed before the claim reached Medicare.
The practice’s records connect what it obtained, what it administered and what it charged. We follow those connections with you, including who directed the billing and what they knew. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
In buy-and-bill, a practice acquires medication, holds it in inventory, administers it and bills for the covered drug and administration services. The purchase invoice describes an acquisition, the medication administration record describes treatment, and the claim asks the payer for money.
The drug code and billed units represent a particular product and quantity. A claim can misstate the drug itself even when the patient received an injection.
Busting Bad Medicine: A Call to Action Addressing Healthcare, Fraud, Waste, and Abuse, published in the Journal of AHIMA in 2017, describes billing for a higher-priced drug while supplying a different, cheaper drug. For the nurse and the biller, that puts the label on the medication and the code on the claim at the center of the same question.
Medicare Part B generally uses average sales price to set drug payment limits. That manufacturer-reported measure differs from the practice’s acquisition price, and the payment limit applies to the HCPCS billing unit. Discounts, vial size, wastage and collections affect what the practice earns.
Paid purchases and no-cost deliveries belong in the same inventory picture. Charitable supplies, patient-specific grants and samples can explain how medication reached the practice outside its purchase ledger. The next questions are what the patient received and whether the practice was entitled to bill for that stock.
In July 2026, Progressive Oncology & Hematology and its owner agreed to pay $1.45 million to resolve the government’s allegations of fraudulent chemotherapy billing. The Frederick, Maryland, practice’s settlement covered distinct allegations about acquisition, shared vials and treatment never administered. The Justice Department credited the inspectors general of Health and Human Services and Veterans Affairs with the investigation.
The government alleged that Progressive billed Medicare, Medicaid and Veterans Affairs for chemotherapy drugs supplied without charge by charitable organizations or through grants for specific patients. We see the inversion: medication supplied to help a patient became, in the government’s account, another bill for taxpayers. For an employee handling those deliveries, the grant paperwork and patient designation explain something a purchase ledger would miss.
The government also alleged that Progressive directed staff to split wastage from single-use vials across patients, then billed as though each patient had received a separate vial. We want to understand who directed the sharing and how the practice turned it into the units it charged.
A further allegation concerned chemotherapy the physician prescribed but never administered at the practice, yet billed to federal and state health insurance programs. We compare the order and claim with the administration record and what staff saw in the treatment room.
Ophthalmic Consultants and its physician agreed to pay $4.8 million in June 2020 to resolve allegations involving Lucentis and Eylea eye treatments. The government alleged that the Sarasota practice used single-use vials across multiple patients to obtain excessive reimbursement from Medicare, TRICARE and the Federal Employees Health Benefits Program.
The Justice Department’s account explained that the vials contained moderate overfill but were designed for single use. The settlement also included an integrity agreement with routine inventory requirements and requirements addressing billing and reimbursement claims.
We see the same practical question in both practices’ allegations: how did the quantity available in the treatment room become the quantity represented to the payer? The answer follows the vial through the patients who received it and the claims submitted for them. Calling the remainder waste does not explain where it actually went.
JW identifies eligible discarded drug from a single-dose container, while JZ attests that there was no discarded amount eligible for payment. Under CMS’s discarded-drug policy, these modifiers apply to drugs separately payable under Medicare Part B. The nationwide JW requirement began January 1, 2017, and JZ became required no later than July 1, 2023.
CMS permits payment for the administered dose and eligible discarded amount up to the quantity on the vial or package label. In its standard claim example, the administered units appear on a line without a modifier and the discarded units on a second line with JW. When no amount is discarded, the drug appears on one line with JZ.
Overfill and waste from multidose containers are outside this single-dose waste policy. CMS also says that when the administered dose is smaller than the billing unit, the claim reports the full unit with JZ. We compare the dose order, vial label, administration and waste records with the billed units, including whether rounding already accounts for the quantity claimed as waste.
CMS expects accurate medical or dispensing records alongside purchasing and inventory records, and accepts software-calculated waste when the documented amount is accurate. For a biller who knows how the waste field gets populated, we connect the calculation in the system to what staff actually discarded.
In a New Jersey oncology matter, the government’s allegation was that the practice administered drugs it was not entitled to bill to Medicare. In February 2017, the practice, its physician and its manager agreed to pay $1.7 million to resolve allegations involving illegally imported chemotherapy drugs that lacked approval for sale in the United States.
The government alleged that the manager ordered the drugs from a foreign distributor and that doctors injected them into patients. The practice then billed Medicare for the drugs and infusion services. The allegation followed the purchase through actual treatment to the request for government payment, with the product’s approval status at the center.
The distributor’s invoice and the identity of the product help explain what entered the practice, while the administration record shows what staff gave the patient. We connect those records to the reimbursement claim instead of stopping when an infusion appears in the chart.
In her criminal plea agreement, an Anchorage rheumatologist admitted that she and the clinic’s office manager submitted claims for medications they knew the clinic had neither purchased nor given to patients. The agreement states that they billed for 4,829 units of the medications while purchasing 369 units between 2009 and 2024.
The physician admitted routinely underdosing patients, using free samples of the prescribed drug or a different medication, injecting expired medication and using stock purchased by other patients for self-injection at home. She also admitted making false statements in medical records about the identity and quantity injected. The office manager knew the records were false and knowingly submitted fraudulent claims.
The plea describes the physician concealing needles beneath a clipboard or behind her back to prevent patients from recognizing the medication. We find that detail telling: a patient could sit through an injection and still be deceived about the drug. Treatment by sleight of hand. A chart saying the prescribed injection occurred could carry the same false account sent to the payer.
The plea also says that the physician and office manager continued billing for medication the clinic had not purchased or administered after learning of the government’s criminal investigation. The agreement records that they knew failing to administer the prescribed medication and dose could allow patients’ conditions to progress and cause irreversible damage.
We connect a particular drug claim to the stock, treatment and decisions behind it. Procurement invoices and no-cost delivery records show how medication entered the practice. Vial and lot inventory, dose orders, administration records and waste records show its path toward a patient or disposal. The claim shows what the practice represented to the payer.
Infusion billing adds a separate quantity: time. Drug units describe medication, while infusion start and stop records describe administration duration. The practice’s administration claim also depends on the service performed, the applicable billing rules and who performed or supervised it. A physician’s billing identity brings those staffing and supervision records into the same review.
The Journal of AHIMA article emphasizes treatment dates, treatment descriptions and nurse or physician signatures, alongside witness accounts. We check those records against what you saw: who prepared the drug, who entered the dose and who directed the claim. The Anchorage admissions show why the person who knows how a record was created can matter as much as the record itself.
Unnecessary treatment can increase both the drug-related care and the visits or infusion services billed around it. In the whistleblower complaint concerning Oncology San Antonio, a physician alleged that the practice changed chemotherapy schedules to increase infusion frequency and visits. The complaint described the alleged change this way:
Standard chemotherapy regimens which are approved for infusions every 2 or 3 weeks were instead split into weekly dosing regimens. These modifications increased the costs associated with office visits and infusions.
The allegation connects the clinical schedule to the money charged for bringing patients back. For someone working in the infusion room or scheduling office, the treatment plan, repeated appointments and administration charges can show different parts of that decision. We examine why the schedule changed and how that change reached the claims.
A drug-billing investigation can also follow the benefits offered to influence prescribing, purchasing or referrals. A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, published in the Journal of Forensic and Investigative Accounting in 2020, explains that kickback arrangements can involve cash or benefits supplied in kind. The question reaches what the practice received in exchange for directing federally paid business.
A free drug can be billed to the government, or it can be the price of a doctor’s prescriptions. We follow both the medication and any prescribing, purchasing or referral commitment that came with it.
CMS’s Open Payments program publishes reported payments from drug and medical device companies to recipients including physicians. We connect a reported payment with the underlying arrangement and the prescribing or purchasing decisions you know about. The useful story is what the business expected in return and how that expectation affected publicly funded health care.
If you know the stock, the dose or the infusion behind a questionable claim, speak with our physician drug billing fraud whistleblower experts. We work with you to build your strongest whistleblower case around what the practice supplied, what it charged and who directed the difference. We bring in healthcare fraud whistleblower lawyers who understand drug and infusion billing, and stay beside you throughout the case.